RSS-Feed abonnieren
DOI: 10.1055/s-0028-1098915
© Georg Thieme Verlag KG Stuttgart ˙ New York
Tibolon erhöht das Rezidivrisiko bei Mammakarzinompatientinnen – neueste Daten aus der LIBERATE-Studie
Publikationsverlauf
Publikationsdatum:
29. Juni 2009 (online)
![](https://www.thieme-connect.de/media/frauenheilkunde-u2d/200903/lookinside/thumbnails/10.1055-s-0028-1098915-1.jpg)
Der Häufigkeitsgipfel der Erkrankung bei Brustkrebspatientinnen liegt im Alter zwischen 50 und 60 Jahren. Frauen in diesem Alter haben von Haus aus klimakterische Beschwerden, die die Frage nach medikamentösen Interventionen aufwerfen. Zudem führt die adjuvante Therapie bei Mammakarzinompatientinnen häufig zu vasomotorischen Symptomen und Knochenverlust. Tibolon kann beiden Symptomen vorbeugen, jedoch war der Einfluss der Substanz auf das Mammakarzinomrezidivrisiko bisher unklar. Die LIBERATE-Studie sollte zeigen, dass Tibolon bei Frauen mit klimakterischen Symptomen das Rezidivrisiko nicht erhöht. Allerdings musste die Studie vorzeitig abgebrochen werden, da das Rezidivrisiko im Tibolon-Arm nach einer medianen Behandlungsdauer von 3 Jahren im Vergleich zu Plazebo signifikant erhöht war. Eine Hormonersatztherapie mit Tibolon bei klimakterischen Beschwerden kann für Patientinnen mit oder nach Mammakarzinom und auch für Patientinnen mit erhöhtem Mammakarzinomrisiko daher nicht empfohlen werden.
Literatur
- 1 Howell A, Cuzick J, Baum M et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet. 2005; 365 60-62
- 2 Goodwin P J, Ennis M, Pritchard K I et al. Risk of menopause during the frst year after breast cancer diagnosis. J Clin Oncol. 1999; 17 2365-2370
- 3 Hickey M, Saunders C M, Stuckey B G. Management of menopausal symptoms in patients with breast cancer: an evidence-based approach. Lancet Oncol. 2005; 6 687-695
- 4 Col N F, Hirota L K, Orr R K et al. Hormone replacement therapy after breast cancer: a systematic review and quantitative assessment of risk. J Clin Oncol. 2001; 19 2357-2363
- 5 Modelska K, Cummings S. Tibolone for postmenopausal women: systematic review of randomized trials. J Clin Endocrinol Metab. 2002; 87 6-23
- 6 Kenemans P, Speroff L. Tibolone: clinical recommendations and practical guidelines. A report of the International Tibolone Consensus Group. Maturitas. 2005; 51 21-28
- 7 Kloosterboer H J. Tibolone: a steroid with a tissue-speciïfc mode of action. J Steroid Biochem Mol Biol. 2001; 76 231-238
- 8 DeGooyer M E, Deckers G H, Schoonen W G et al. Receptor profiling and endocrine interactions of tibolone. Steroids. 2003; 68 21-30
- 9 Lundström E, Christow A, Kersemaekers W et al. Effects of tibolone and continuous combined hormone replacement therapy on mammographic breast density. Am J Obstet Gynecol. 2002; 186 717-722
- 10 Valdivia I, Campodónico I, Tapia A et al. Effects of tibolone and continuous combined hormone therapy on mammographic breast density and breast histochemical markers in postmenopausal women. Fertil Steril. 2004; 81 617-623
- 11 Conner P, Christow A, Kersemaekers W et al. A comparative study of breast cell proliferation during hormone replacement therapy: effects of tibolone and continuous combined östrogen-progestogen treatment. Climacteric. 2004; 7 50-58
- 12 Beral V. Million Women Study Collaborators . Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2003; 362 419-427
- 13 Opatrny L, Dell'Aniello S, Assouline S et al. Hormone replacement therapy use and vartiations in the risk of breast cancer. Br J Obstet Gynaecol. 2008; 115 169-175
- 14 Cummings S R, Ettinger B, Delmas P D et al. The effects of tibolone in older postmenopausal women. N Engl J Med. 2008; 359 697-708
- 15 Kroiss R, Fentiman I S, Helmond F A et al. The effect of tibolone in postmenopausal women receiving tamoxifen after surgery for breast cancer: a randomised, double-blind, placebo-controlled trial. Br J Obstet Gynaecol. 2005; 112 228-233
- 16 Dimitrakakis C, Keramopoulos D, Vourli G et al. Clinical effects of tibolone in postmenopausal women after 5 years of tamoxifen therapy for breast cancer. Climacteric. 2005; 8 342-351
- 17 Pollow K, Schaffrath M, Kölbl H et al. Phase II study of goserelin adjuvant therapy combined with exemestane with or without tibolone in premenopausal women with receptor positive, node negative mammary carcinoma: ADAGIO Study. Geburtsh Frauenheilk. 2005; 65 612-619
- 18 Kubista E, Planellas Gomez J, Dowset M et al. Effect of tibolone on breast cancer cell proliferation in postmenopausal ER+ patients: results from STEM trial. Clin Cancer Res. 2007; 13 4185-4190
- 19 Bundred N J, Kenemans P, Beckmann M W et al. Effect of tibolone on breast cancer recurrence: LIBERATE trial bone sub-study. Cancer Res. 2009; 69 66
- 20 Cline J M, Register T C, Clarkson T B. Effects of tibolone and hormone replacement therapy on the breast of cynomolgus monkeys. Menopause. 2002; 9 422-429
- 21 Verheul H A, van Iersel M L, Delbressine L P et al. Selective tissue distribution of tibolone metabolites in mature ovariectomized female cynomolgus monkeys after multiple doses of tibolone. Drug Metab Dispos. 2007; 35 1105-1111
- 22 Suzuki T, Miki Y, Nakata T et al. Steroid sulfatase and estrogen sulfotransferase in normal human tissue and breast carcinoma. J Steroid Biochem Mol Biol. 2003; 86 449-454
- 23 Million Women Study Collaborators . Breast cancer and hormone-replacement therapy in the Million Women Study. The Lancet. 2003; 362 419-427
- 24 Holmberg L, Anderson H. for the HABITS steering and data monitoring committees . HABITS (hormonal replacement therapy after breast cancer – is it safe?), a randomised comparison: trial stopped. The Lancet. 2004; 363 453-455
Prof. Dr. med. M. Untch
Chefarzt der Klinik für Gynäkologie und Geburtshilfe und Leiter des Interdisziplinären Brustzentrums · HELIOS-Klinikum Berlin-Buch
Schwanebecker Chaussee 50
13125 Berlin
eMail: michael.untch@helios-kliniken.de